FINWIRES · TerminalLIVE
FINWIRES

Indian Equities Rally on Monday as US-Iran Peace Deal Lifts Sentiment

By

FINWIRES Analysis

The rally is geopolitically driven, with lower crude the key transmission channel for oil-importing India rather than domestic fundamentals. The Vedanta demerger creating four sector-focused listings and Bharti's cashless Airtel Africa stake increase are structural corporate stories that will outlast the headline-driven sentiment. With the catalyst now priced, attention shifts to monsoon progress and earnings for sustainable direction.

Key Takeaways

  • Rally is geopolitical; cheaper crude is the channel
  • Vedanta demerger creates four sector-focused listings
  • Monsoon and earnings drive the next leg

Indian benchmark indices climbed nearly 1% on Monday as investors welcomed a peace agreement between the U.S. and Iran.

The truce ended nearly four months of conflict, easing geopolitical concerns. The agreement boosted risk appetite across global markets and triggered broad-based buying in Indian equities.

The BSE Sensex rose 736.38 points, or 1%, to close at 76,264.33, while the NSE Nifty 50 gained 231.00 points, or also 1%, to settle at 23,853.90.

Lower crude oil prices added to the positive mood.

Analysts believe market participants will now focus on the progress of the monsoon season, potential El Niño-related risks, and the upcoming earnings season for clues on corporate growth and profitability.

In corporate developments, four Vedanta Group companies - Vedanta Aluminium Metal (NSE:VAML, BOM:544780), Vedanta Power (NSE: VEDPOWER, BOM:544781), Vedanta Oil & Gas (NSE:VOGL, BOM:544782), and Vedanta Iron & Steel (NSE:VISL, BOM:544784) - began trading on Indian exchanges, completing the group's demerger into sector-focused businesses.

Meanwhile, Bharti Airtel (NSE:BHARTIARTL, BOM:532454) said nearly all shareholders approved a transaction that will increase its effective stake in Airtel Africa to about 79%. The deal involves the issuance of equity shares to a promoter group entity and does not require any cash outflow.

Related Articles

Asia

Singapore Regulator to Streamline 'Single Family Office' Framework

The Monetary Authority of Singapore has revised its "single family office" (SFOs) framework to streamline the process for SFOs to establish operations in Singapore, according to a MAS release.An SFO in Singapore is a privately held corporate entity set up by one "ultra-high-net-worth" family to manage assets, investments, and wealth of a single family.The registration protocols have been simplified, effective June 15, with offices required to notify MAS of their operations through a MAS-licensed bank.Annual reporting has been made more straightforward for SFOs, with information on total assets under management and the name of its bank.

^STI
Asia

Klevo Rewards Plans Stablecoin Trial Launch by June 30; Shares Fall 4%

Klevo Rewards (ASX:KLV) said it plans to launch a trial of its KLVAUD Australian dollar-backed stablecoin by June 30, according to a Monday filing with the Australian bourse.The company's Fly Wallet subsidiary received legal advice indicating that the stablecoin may qualify as an eligible stablecoin under the current regulatory framework, subject to conditions, per the filing.KLVAUD is planned to be fully backed one-to-one by Australian dollars held in segregated reserve accounts, and aims to support Fly Wallet's broader payments system, the company said.Klevo Rewards shares fell 4% in recent Monday trade.

ASX:KLV
Asia

Bio-Thera Solutions Gets Europe's Results on On-Site Inspection

Bio-Thera Solutions (SHA:688177) received the results of the European Union's inspection of its Yonghe manufacturing facility, according to a Shanghai bourse filing on Monday.The French National Agency for the Safety of Medicines and Health Products conducted an inspection on the site between Feb. 4 and Feb. 12.The European Medicines Agency handed a GMP or good manufacturing practice certificate to the company after the factory's drug substance operations passed regulatory standards. However, the regulator found deficiencies in the deviation management measures for the finished formulation of the drugs.

SHA:688177